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Cutting balloon angioplasty of autogenous
infrainguinal bypasses: Short-term safety
and efficacy
Robert Garvin, MD,a and Thomas Reifsnyder, MD,b Pittsburgh, Pa, and Baltimore, Md
Purpose: This study evaluated the safety and efficacy of cutting balloon angioplasty in the treatment of infrainguinal vein
bypass graft stenosis.
Methods: Data from a prospective database, supplemented by chart review, were obtained on all patients who underwent
cutting balloon angioplasty of lower extremity vein bypass grafts at a single institution during a 4-year period.
Noninvasive duplex ultrasound imaging of grafts, along withmeasurement of ankle-brachial indices and digital pressures,
was performed on all patients before and after treatment with the cutting balloon. Efficacy of cutting balloon angioplasty
and procedural complications were analyzed. Data from noninvasive vascular testing were compared using the two-tailed
paired Student t test. Patency rates were calculated using the Kaplan-Meier method. Differences in patency rates were
compared using the log-rank test.
Results: From July 2002 to February 2006, 109 cutting balloon angioplasties were performed on 70 bypasses in 61
patients. There were 12 complications in 109 procedures (11%), only one of which required immediate operative
intervention. Initial technical success was 96%. Noninvasive vascular testing indicators significantly improved immedi-
ately after intervention: peak systolic graft velocity decreased from 360  158 cm/s to 143  67 cm/s (P < .001),
ankle-brachial index improved from 0.55  0.3 to 0.85  0.2 (P < .001), and digital pressure increased from 31  30
mm Hg to 62  32 mm Hg (P < .001). Patency rates at 6 months according to the Kaplan-Meier method were primary
patency, 48% (95% confidence interval [CI], 0.36 to 0.60); assisted primary patency, 72% (95% CI, 0.61 to 0.83); and
secondary patency, 99% (95% CI, 0.97 to 1.00). At 6 months, cumulative limb salvage was 94% (95% CI, 0.89 to 1.00).
Conclusions:Cutting balloon angioplasty of infrainguinal vein bypass graft stenosis is technically feasible but is associated
with a relatively high complication rate and a relatively low short-term patency rate. ( J Vasc Surg 2007;46:724-30.)Infrainguinal vein bypass grafts are prone to develop ste-
noses over time, thereby threatening the longevity of the
bypass grafts. These stenotic lesions can be repaired using
open surgical techniques or percutaneous interventions. Cur-
rently, there is no consensus about optimal treatment of these
stenotic lesions. Various methods have been used for percuta-
neous treatment of failing bypass grafts, including standard
balloon angioplasty and mechanical atherectomy.
A relatively new technique, cutting balloon angio-
plasty, has been used in the coronary circulation for nearly
a decade but has seen little use in the peripheral circula-
tion.1-5 The cutting balloon contains 3 to 4 small athe-
rotomes positioned longitudinally along the balloon that
cause controlled linear fractures of the atherosclerotic
plaque or myointimal lesion. Despite the paucity of data
supporting the use of cutting balloon angioplasty in the
treatment of infrainguinal bypass graft stenosis, several
centers are now using the cutting balloon to treat these
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724failing grafts in select patients. To define the safety and
efficacy of cutting balloon angioplasty to treat infrainguinal
vein bypass graft stenosis, we report our single-center ex-
perience during a 4-year period.
METHODS
A retrospective chart review was performed on all pa-
tients who underwent cutting balloon angioplasty of lower
extremity vein bypass grafts at Western Pennsylvania Hos-
pital between July 2002 and February 2006. Patients were
identified from a prospective database maintained by the de-
partment of interventional radiology. All bypasses were per-
formed by one of two vascular surgeons. Patients were
excluded if their bypass had been performed at a different
institution, if the medical record data were incomplete, or if
the bypass originated proximal to the common femoral
artery.
All patients participated in a routine postoperative sur-
veillance protocol in which history and physical examina-
tion were supplemented with noninvasive vascular testing.
Ankle-brachial indices (ABI), digital pressures, and duplex
ultrasound (DU) scanning of the entire bypass were per-
formed at regular postoperative intervals in a peripheral
vascular laboratory accredited by the Intersocietal Commis-
sion for the Accreditation of Vascular Laboratories. These
studies were typically obtained at 1, 3, 6, 9, 12, 18, and 24
months postoperatively, and yearly thereafter.
The criteria for significant graft stenosis was defined as
an absolute peak systolic velocity 300 cm/s or velocity
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scan. Patients identified as having significant graft stenosis
were consented for diagnostic angiography and possible
percutaneous intervention. In addition, patients under-
went diagnostic angiography if there was clinical suspicion
that the bypass was failing even though the DU scan could
not accurately identify the stenotic lesion. Clinical signs of
failing bypasses included progression of symptoms, change
in pulse status by physical examination, or a decrease in the
ABI by 0.15.
All interventions were performed by one of two vascu-
lar surgeons or one of two interventional radiologists.
Cutting balloon angioplasty was restricted to lesions2 cm
long. The smallest and largest vessels treated with the
cutting balloon were 2 mm and 6 mm by inside diameter,
respectively. In most cases, cutting balloon angioplasty was
used as the sole intervention. In select cases, however, it was
combined with the use of standard percutaneous translu-
minal angioplasty (PTA) in one of two scenarios: (1) cut-
ting balloon angioplasty was used as a “bailout” procedure
after suboptimal results were obtained with standard bal-
loon angioplasty, or (2) cutting balloon angioplasty was
used to predilate a lesion, followed by further dilation with
a standard angioplasty balloon. The choice of treatment
was left to the discretion of the surgeon or interventional
radiologist performing the procedure.
Access to the arterial circulation was obtained most
commonly using a retrograde approach in the contralateral
common femoral artery. In select cases, an antegrade
femoral approach, brachial approach, or direct graft
puncture was used. Once diagnostic angiography con-
firmed the presence of a significant stenosis, a 6F sheath
was placed and the patient was anticoagulated. Activated
clotting times were maintained at therapeutic levels
throughout the procedures.
A 0.014-inch or 0.018-inch guidewire was then used to
cross the lesion using either a monorail or coaxial system.
The cutting balloon size was chosen by measuring the
diameter of the normal vessel adjacent to the lesion with
electronic calipers and then slightly under-sizing the bal-
loon at the discretion of the interventionalist. Once posi-
tioned, the cutting balloon was inflated at least twice for
each lesion. The balloon was inflated for 30 seconds per
inflation, with the balloon catheter withdrawn, rotated, and
advanced back across the lesion between inflations. Using a
mechanical inflation device, inflation pressures typically
ranged from 6 to 10 atm. After removal of the angioplasty
catheter, completion angiography was performed. The
arterial sheath was pulled once the activated clotting
time had returned to normal. Intra-arterial nitroglycer-
ine was liberally used to prevent and treat vasospasm
during the procedures.
Postprocedure noninvasive testing, including ABI, dig-
ital pressure, and DU imaging of the entire bypass, was
performed later the same day or the next morning. Patients
were then re-entered into the surveillance protocol.
Data collection included patient demographics, opera-
tive data, the time from surgery to the intervention, data(graft velocities, ABIs, and digital pressures) before and
after the procedure, time of follow-up, initial technical
success rate, graft patency rates, and limb salvage. Proce-
dural complications were recorded, including graft rupture,
graft dissection, graft thrombosis, and need for emergency
conversion to an open surgical procedure.
All data were entered into a computer database and
statistical analysis using StatView 5.0.1 for Windows (SAS
Institute, Inc, Cary, NC; Microsoft, Redmond, Wash) was
performed using the two-tailed paired Student t test to
compare data obtained from noninvasive vascular testing.
The product-limit method (Kaplan-Meier) was used to
estimate graft patency, with log-rank tests used to compare
differences in patency curves. The Institutional Review
Board of the Western Pennsylvania Hospital, Pittsburgh,
Pennsylvania, approved the study.
RESULTS
Between July 2002 and February 2006, 118 cutting
balloon angioplasties were performed on 78 bypasses in 69
patients. After excluding four patients who were referred
from outside institutions (these patients had no follow-up
data), three patients who had incomplete medical record
data, and one patient who had cutting balloon angioplasty
performed at the aortic anastomosis of an aortofemoral
graft, there were a total of 109 procedures performed on 70
bypasses in 61 patients. Patient demographic and bypass
graft data are listed in Table I.
All bypasses were constructed with autogenous vein
from various harvest sites, with 30 (43%) of 70 bypasses
containing vein other than great saphenous vein. The target
vessels were below the knee in 64 (91%) of 70 bypasses. The
location of the stenosis was variable, with 41% of stenoses
occurring at one of the anastomoses. The average number
of stenoses per graft was 1.3 (median, 1; range, 1 to 4). The
time from original bypass surgery to cutting balloon angio-
plasty was a mean of 10 months (median, 7 months; range,
1 to 51 months). The size of the cutting balloon depended
on the size of the vein graft, ranging from 2.0 mm to 6.0
mm, with 85% of the interventions using balloons 2.5 mm
to 4.0 mm in diameter.
The offending lesion was successfully opened in 105 of
109 procedures, yielding an initial technical success rate of
96%. Of the four cases deemed a technical failure, each
lesion was successfully crossed with a wire, but residual graft
stenosis of 30% remained after treatment. In five cases,
primary treatment was performed with a standard angio-
plasty balloon, but a cutting balloon was then used as a
“bailout” maneuver due to significant residual stenosis.
The cutting balloon was used to predilate a lesion in 15
interventions, followed by further dilation with a standard
angioplasty balloon. In 89 cases, cutting balloon angio-
plasty was used exclusively as the sole intervention.
Table II summarizes the preprocedure and postproce-
dure noninvasive vascular testing. ABIs could not be calcu-
lated in 16 (26%) of 61 patients because of incompressible
vessels. In another 13 (21%) patients, toe pressures were
unavailable because of prior first toe amputation. There was
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indicators immediately after cutting balloon angioplasty.
Kaplan-Meier patency curves and limb salvage rates for
Table I. Patient demographics and bypass graft data
Demographic* and bypass data Number
Age 71  11 years
Gender
Male 35
Female 26
Comorbidities (n 56)
Hypertension 48
Diabetes 40
Coronary disease 34
Smoking 28
Hyperlipidemia 14
Renal insufficiency 13
Dialysis 2
Medications (n 56)
Aspirin 40
-blocker 39
Statin 21
ACE inhibitor 19
Plavix 17
Coumadin 13
Lovenox 3
Bypass location (n 70)
Femoral-popliteal
Above knee 6
Below knee 4
Femoral-tibial 40
Femoral-distal 6
Popliteal-distal 14
Vein harvest location (n  70)†
Reversed great saphenous 16
Nonreversed great saphenous 11
Reversed small saphenous 5
Nonreversed small saphenous 1
Reversed basilic 11
Nonreversed basilic 6
Reversed cephalic 6
Nonreversed cephalic 0
Deep femoral 1
In situ 2
Unknown harvest site 20
Spliced vein from 2 sites 14
Bypass indication (n  70)
Ischemia with rest pain 10
Ischemia with tissue loss 42
Acute ischemia 2
Claudication 0
Unknown 16
Stenosis location (n  109)
Proximal anastomosis 14
Proximal graft 18
Middle graft 22
Distal graft 24
Distal anastomosis 31
ACE, Angiotensin-converting enzyme.
Plavix, Sanofi-Aventis, Bridgewayer, NJ.
Coumadin, Bristol-Myers Squibb, Princeton, NJ.
Lovenox, Sanofi-Aventis, Bridgewayer, NJ.
*Complete demographic data was available for 56 of 61 patients.
†14 of 70 patients had multiple harvest sites, so total from all harvest sites is
70.all 109 interventions (all cases) are shown in Figs 1 and 2.Median length of follow-up was 6 months (mean, 8
months; range, 1 to 38 months). The cumulative primary
patency rate at 6 months was 48% (95% confidence interval
[CI], 0.36 to 0.60; standard error [SE], 0.063). The cu-
mulative assisted primary patency rate at 6 months was 72%
(95%CI, 0.61 to 0.83; SE, 0.056). The cumulative second-
ary patency rate at 6 months was 99% (95% CI, 0.97 to
1.01; SE, 0.012). Cumulative limb salvage at 6 months was
94% (95% CI, 0.89 to 1.00; SE, 0.028). Of note, 11 of 70
bypasses underwent repeat intervention with cutting bal-
loon angioplasty during the study period (8 had 1 repeat
intervention; 3 had 2 repeat interventions), accounting for
the number at risk being 84 instead of 70 for calculation of
Table II. Results of non-invasive vascular testing
Noninvasive study Preintervention Postintervention P
Peak systolic velocity
(cm/s) 360  158 143  67 .001
Ankle-brachial index 0.55  0.3 0.85  0.2 .001
Digital pressure
(mm Hg) 31  30 62  32 .001
Results compared using two-tailed paired Student t test.
Fig 1. Cumulative patency (primary patency, blue line; assisted
primary patency, red line; and secondary patency, dotted line) for
all cases. Censor times are noted by squares for primary patency,
triangles for assisted primary patency; and circles for secondary
patency.
Fig 2. Cumulative limb salvage for all cases, with circles repre-
senting censor times.the Kaplan-Meier patency curves.
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treatment with cutting balloon angioplasty were analyzed
separately. When compared with the group as a whole,
there was no statistical difference between the patency
curves (all cases vs cutting balloon angioplasty alone). The
median length of follow-up for this group was also 6
months (mean, 8 months; range, 1 to 38 months). The
cumulative primary patency rate at 6 months for this group
was 43% (95% CI, 0.29 to 0.57; SE, 0.071, P  .367) as
shown in Fig 3. The cumulative assisted primary patency
rate at 6months was 67% (95%CI, 0.54 to 0.81; SE, 0.067,
P  .548). The cumulative secondary patency rate at 6
months was 99% (95% CI, 0.96 to 1.01; SE, 0.015, P 
.609), and the limb salvage rate at 6 months was 93% (95%
CI, 0.86 to 1.00; SE, 0.036; P  .567).
Also analyzed separately were the 15 cases that under-
went predilation treatment with the cutting balloon, fol-
lowed by standard PTA. When compared with the group
that underwent exclusive treatment with the cutting bal-
loon, no statistical differences were found in patency rates
at 6 months: primary patency was 47% (95% CI, 0.17 to
0.76; SE, 0.151, P  .204), assisted primary patency was
75% (95% CI, 0.49 to 1.00; SE, 0.129, P .606), second-
ary patency was 93% (95% CI, 0.80 to 1.06; SE, 0.064, P
.991), and limb salvage was 93% (95% CI, 0.80 to 1.06; SE,
0.064, P  .646).
No deaths and no systemic complications occurred in
this series. There were 12 local complications (11%) in 109
interventions, including 8 graft ruptures, 2 graft dissec-
tions, 1 graft thrombosis, and 1 incidental finding of a late
graft aneurysm after cutting balloon angioplasty. The eight
ruptures occurred in patients who were treated with the
cutting balloon alone. Five of these grafts were constructed
from great saphenous vein, and three were constructed
from spliced basilic vein. Six of the graft ruptures were
mid-graft lesions, and two were lesions at the distal anasto-
mosis. The anastomotic ruptures occurred in grafts that
were 6 weeks old and 30 months old, respectively.
Overall, 41% of the interventions in this series occurred
at an anastomotic site, with no higher risk of rupture
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Fig 3. Cumulative primary patency for all cases (red line) vs
cutting balloon angioplasty (CBA) alone (dotted line). Censor
times are noted by triangles for all cases, and circles for CBA alone.compared with other sites. Of note, one of the eightpatients who experienced a graft rupture required emer-
gency operative intervention. This patient initially pre-
sented with a thrombosed bypass, underwent cutting bal-
loon angioplasty of a proximal graft stenosis, and then was
started on thrombolysis. She underwent the first thrombol-
ysis check at 8 hours and was found to have extravasation
from the site of cutting balloon angioplasty. She required
ligation of the graft in the operating room to control
hemorrhage at the site of graft rupture. Two days later
she underwent below the knee amputation for progressive
ischemia because she had no further available conduit for a
distal bypass and she had active infection in her foot pre-
cluding the use of prosthetic conduit. The remaining seven
graft ruptures were managed without surgical intervention
by using manual compression of the graft or prolonged
inflation of a standard angioplasty balloon at the site of
rupture to achieve hemostasis.
One of the two graft dissections occurred in a patient
who was predilated with a cutting balloon, followed by
dilation with a standard balloon. This dissection resulted in
complete thrombosis of the bypass after attempting repair
with prolonged inflation of a standard angioplasty balloon.
This patient received immediate therapy with thrombolyt-
ics, but the graft could not be salvaged. The other dissec-
tion occurred in a graft treated with the cutting balloon
alone. The dissection was treated with inflation of a stan-
dard balloon and the bypass remained patent at 25 months.
The graft thrombosis occurred in a patient whose vein
graft was treated initially with a standard balloon but re-
quired cutting balloon angioplasty as a bailout for what
appeared to be a retained valve leaflet. During manipula-
tion, the graft went into vasospasm that was refractory to
treatment with intra-arterial nitroglycerine. The patient
also had a subtherapeutic activated clotting time during the
procedure. The bypass was salvaged with immediate insti-
tution of thrombolytic therapy, but a 5-day hospital stay
was required. The graft remained patent at 38 months.
The single late graft aneurysm was noted incidentally at
2 months during surveillance DU imaging of the bypass.
This was an asymptomatic mid-graft aneurysm measuring
0.84 cm  0.60 cm that occurred at the site of previous
treatment with a standard balloon that failed and required
cutting balloon angioplasty as a bailout procedure. This
aneurysm was followed up on subsequent surveillance DU
imaging studies and had not increased in size at 30 months’
follow-up.
DISCUSSION
Long-term patency of autogenous infrainguinal bypass
grafts is significantly improved with routine postoperative
surveillance accompanied by revision of stenotic bypass
segments.6-9 The subsequent assisted primary patency of
appropriately revised bypasses is equivalent to normally
functioning bypasses that have never been revised.9 Repair
of the stenotic infrainguinal bypass graft has traditionally
been achieved with acceptable results using open vein patch
angioplasty or short-segment graft replacement.10With the
evolution of endovascular techniques, vein graft stenoses
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small but finite morbidity sometimes associated with chal-
lenging open revisional cases.
Currently, there is no consensus about which is the best
method of treating infrainguinal vein graft stenosis. Several
studies have compared open surgical revision with PTA,
but no clear conclusions can be drawn from the existing
data.11-15 PTA and percutaneous mechanical atherectomy,
originally used to treat native vessel atherosclerotic disease,
are now being used to treat these stenotic lesions in vein
bypass grafts; however, 1-year patency rates after standard
PTA are variable, with rates as low as 44% to 53%.16-17
Patency rates after percutaneous mechanical atherectomy
are somewhat higher in the short term, but have higher
complication rates, more cumbersome delivery systems,
and higher expense.18-20 The patency rates for appropriate
de novo atherosclerotic lesions treated with PTA are higher
than patency rates of vein graft stenoses undergoing the
same treatment.
This finding suggests that the process of myointimal
hyperplasia, one of the major causes of vein graft stenosis,
does not respond as well to percutaneous treatment that is
successful for native vessel disease. Therefore, an alternative
percutaneous method of treatment may be necessary to
more effectively address the problem of myointimal hyper-
plasia. This study investigates one of these alternatives,
cutting balloon angioplasty, to percutaneously treat autog-
enous infrainguinal vein graft stenosis.
The concept of using a cutting balloon was first devel-
oped for use in the coronary circulation 10 years ago,
initially being used to treat coronary artery ostial lesions
and, subsequently, resistant native vessels lesions and in-
stent restenosis.21-23 The cutting balloon is made with
three to four small atherotomes positioned longitudinally
along the balloon. These atherotomes cause controlled
linear fractures of the atherosclerotic plaque or myointimal
lesion, thereby reducing intimal trauma and reducing the
hoop stress associated with conventional PTA. The reduc-
tion in intimal traumamay lead to less chance of subsequent
development of myointimal hyperplasia, whereas the re-
duction in hoop stress theoretically would leave less chance
for local complications such as graft rupture, thrombosis, or
dissection compared with standard balloon angioplasty.
Furthermore, when considering the process of myointimal
hyperplasia, there should be less chance of elastic recoil of
the fibrous lesion with the cutting balloon compared with a
standard angioplasty balloon because the atherotomes will
produce small microsurgical incisions in the fibrous cap-
sule, making the lesion less resistant to dilatation.
Initial nonrandomized data from the cardiology litera-
ture suggested a benefit to cutting balloon angioplasty
compared with conventional balloon angioplasty in treat-
ing native vessel disease,24 but as experience has grown in
the cardiology literature, randomized data have shown that
cutting balloon angioplasty is not superior but is equivalent
to standard PTA when treating atherosclerotic lesions.25
However, results of treatment for in-stent restenosis, which
represents a model of myointimal hyperplasia, show thatpatency rates may be improved with the use of the cutting
balloon.22,26 It would follow that the cutting balloon could
also play a role in treating myointimal hyperplasia that
causes infrainguinal vein graft stenosis.
Although the cutting balloon has now found a niche for
use in the coronary circulation, the role of its use in the
peripheral circulation remains undefined. There are few
reports of its use outside of the coronary circulation other
than to treat failing hemodialysis access grafts and pulmo-
nary artery branch stenosis.1-3 Currently, the only two
published manuscripts on cutting balloon angioplasty for
infrainguinal bypass graft stenosis are retrospective series
with small numbers.4-5
In 2002, Engelke et al4 reported results of cutting
balloon angioplasty of 16 anastomotic lesions in 15 grafts.
These data were obtained from a heterogeneous patient
population containing five prosthetic inflow grafts and
various infrainguinal bypasses. Most of the bypasses were
constructed with polytetrafluoroethylene (PTFE); only
four of 15 bypasses were constructed with autogenous vein.
The initial technical success rate was 94%, and no compli-
cations were reported. The primary and secondary graft
patency rates were 84% and 92%, respectively, at 6
months’ postintervention. Although the patency rates
are difficult to interpret in this heterogeneous popula-
tion, they do show that cutting balloon angioplasty is
technically feasible in the treatment of lower extremity
bypass graft anastomotic stenosis.
In 2004, Kasirajan et al5 reported results of cutting
balloon angioplasty of 19 autogenous infrainguinal bypass
grafts in 19 patients. The technical success rate was 100%,
and no complications were reported. However, ABIs and
digital pressures were not measured, and no statistical anal-
ysis of DU velocity data was reported. The restenosis rate
was reported in crude numbers without Kaplan-Meier esti-
mates, limiting our ability to draw firm conclusions about
durable patency. Despite these limitations, the Kasirajan
study was the first published series of cutting balloon
angioplasty to treat autogenous infrainguinal bypasses.
Our study reports the results of cutting balloon angio-
plasty on autogenous infrainguinal bypasses, most of which
had target vessels below the knee. The location of the
stenoses was variable, representing both anastomotic le-
sions and mid-graft lesions. Our patients were followed up
according to a strict postoperative surveillance protocol,
enabling identification of bypass restenosis, graft patency,
and limb salvage after treatment with the cutting balloon.
Our technical success rate was high, consistent with the
results of Engelke and Kasirajan. Our Kaplan-Meier pa-
tency rates are much lower than those reported by Engelke
et al, presumably due to the small number of patients, the
heterogeneous patient population, and the high incidence
of large-diameter PTFE inflow grafts in the Engelke series.
In comparison, 91% of the bypasses in our series had target
vessels below the knee, and 85% of the vein grafts required
balloons sized between 2.5 and 4.0 mm, signifying the
small size of the grafts treated in our series.
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complication rate associated with cutting balloon angio-
plasty of infrainguinal vein bypass grafts is better defined.
The complication rate encountered represents mostly mi-
nor local complications, all but one of which was treated by
percutaneous methods at the time of intervention. Pub-
lished manuscripts in the cardiology literature have shown
that complications from the cutting balloon are infrequent
but do occur, including case reports of vein graft dissection
and pericardial tamponade from vessel rupture.27-29
The most frequently encountered complication in our
series was graft rupture. All eight cases occurred in patients
treated exclusively with the cutting balloon, raising the
question of whether our method of under-sizing the bal-
loon was inadequate, thus leading to the increased fre-
quency of this complication. Also, perhaps the durability of
the vein influenced the rate of rupture, because three of the
eight ruptures occurred in bypasses constructed of spliced
arm vein. Two of the ruptures occurred at distal graft
anastomoses. Considering that the distal anastomotic rup-
ture that occurred in a 6-week-old graft was salvaged with
prolonged standard PTA balloon inflation, and no pseudo-
aneurysm was found on follow-up, we believe that the
suture line was likely not disrupted. The other complica-
tions of dissection and late aneurysm formation did not
occur with enough frequency to make predictions about
why they occurred. The case of graft thrombosis may have
been due to factors unrelated to the cutting balloon.
The question still remains: Which method of treating
infrainguinal vein graft stenosis yields the best results? With
the advancement of percutaneous techniques, open surgi-
cal revision is the gold standard against which these other
treatments must be compared. In a recent series by Kreien-
berg et al,30 the 5-year secondary patency rates for bypasses
revised with vein patch angioplasty or vein graft interposi-
tion were 75% to 79%. In almost all cases, open surgical
revision is technically feasible with minimal morbidity.
However, in select patients, open surgical revision may
present unique challenges that make percutaneous inter-
ventionmore attractive. In patients with little or no remain-
ing autogenous vein, those who have severely scarred sur-
gical wounds, or those who have anatomically tunneled
bypasses, percutaneous intervention may obviate some of
the technical problems and morbidity associated with open
surgical revision.
We did not directly compare standard balloon angio-
plasty with cutting balloon angioplasty in this series, but
from historical data the short-term patency rates appear to
be similar.16,17 Although the complication rate in our series
was relatively high, we were liberal in what we defined as a
complication, and most of the complications can be con-
sidered minor. We have shown that percutaneous treat-
ment of infrainguinal vein graft stenosis with cutting bal-
loon angioplasty is feasible, with a high initial technical
success rate; however, the patency rates over the short term
are significantly lower than the long-term patency rates
shown with open revision. Whether or not cutting balloonangioplasty offers a benefit in long-term patency compared
with standard PTA angioplasty remains to be seen.
Proponents of cutting balloon angioplasty could criti-
cize this study because most of the patients were treated
exclusively with the cutting balloon. However, acceptable
angiographic results were often obtained despite the use of
a balloon that was routinely slightly under-sized, thus mak-
ing the use of a subsequent dilation with a standard balloon
seem unwarranted. One could argue that more generous
under-sizing of the cutting balloon, followed by further
dilation with a slightly larger standard balloon, could both
decrease the complication rate and possibly increase the
patency rate. This technique was used in a small subset of
patients, but when we compared results of this technique
with the use of cutting balloon angioplasty alone in our
series, no benefit in patency was noted in those patients
who underwent cutting balloon angioplasty followed by
standard balloon angioplasty.
CONCLUSION
Although this study does not directly compare open vs
percutaneous revision, based on the safety and efficacy
demonstrated in this series, we cannot recommend the
routine use of cutting balloon angioplasty as a first-line
therapy to treat lower extremity vein bypass graft stenosis.
However, as technology and experience improve, we sus-
pect that there will be a subset of patients in whom a
percutaneous technique will be preferable. Currently sev-
eral questions still remain:
● What subset of patients will be better served with
percutaneous intervention instead of open revision?
● Which method of percutaneous intervention is supe-
rior, cutting balloon angioplasty or standard balloon
angioplasty?
● Are there certain lesions that may respond better to
standard balloon angioplasty and ones that may re-
spond better to cutting balloon angioplasty?
With more experience and clinical research we hope to
answer some of these questions about revision of infrain-
guinal vein bypass graft stenoses. The ultimate solution to
determine the best treatment is a prospective randomized
trial comparing the various open and percutaneous tech-
niques. However, with the multitude of bypass configura-
tions such as in situ, reversed vein, nonreversed anatomi-
cally tunneled, and various composite grafts, obtaining
valid information will take considerable time and effort. In
the absence of prospective randomized data to answer these
questions, the contemporary vascular surgeon should be
facile with all possible treatment modalities including open
and percutaneous techniques, and should be aware of the
risks and benefits associated with each intervention.
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